Previous 10 | Next 10 |
Applied DNA Sciences (NASDAQ:APDN) has dropped -12.80% pre-market after pricing its share offering. The company entered into a securities purchase agreement with an institutional investor for the sale of 1,496,400 shares of its common stock at $2.80/share. Gross proceeds is estimated to ...
Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it has entered into a securities purchase agreement with an institutional investor, providing for the purchase and sale of 1...
- First Published Study Demonstrates LinearDNA Pan-Cancer and Colon Cancer Neoantigen Vaccines – - LinearDNA Vaccines Elicits Strong Antigen-specific Immune Responses and Significantly Reduces Tumor Growth in Animal Cancer Models - - Manuscript Summarizing Findi...
Applied DNA (NASDAQ:APDN) has recorded the biggest intraday loss in more than a year to reach a new 52-week low after the life sciences company reported Q1 revenue for fiscal 2021 on Thursday after the close. Despite a twofold rise in the top line, the firm’s net loss has narrowed only...
Gainers: Orphazyme ORPH +22%. Y-mAbs Therapeutics YMAB +11%. Oscar Health (NYSE:OSCR) +9%. Theravance Biopharma TBPH +9%. VistaGen Therapeutics (NASDAQ:VTGN) +8%. Losers: ProQR Therapeutics PRQR -72%. Senseonics SENS -19%. PetVivo P...
Applied DNA Sciences, Inc. (APDN) Q1 2022 Earnings Conference Call February 10, 2022 4:30 P.M. ET Company Participants Sanjay Hurry - Investor Relations Beth Jantzen - Chief Financial Officer James Hayward - Chairman, President & Chief Executive Officer Conference Call Participants Jonath...
Applied DNA Sciences press release (NASDAQ:APDN): Q1 GAAP EPS of -$0.63. Revenue of $4.17M (+157.4% Y/Y). Shares -1%. For further details see: Applied DNA Sciences GAAP EPS of -$0.63, revenue of $4.17M
- Revenues of $4.2 Million Increased 158% Year-over-Year and 37% Sequentially - - Momentum Continues into FQ2 with January Revenues of Approximately $2.0 Million - - Company to Hold Conference Call and Webcast Today, Thursday, February 10, 2022, at 4:30 PM ET - ...
Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in Polymerase Chain Reaction (PCR)- based DNA manufacturing and nucleic acid-based technologies, today announced that it will report fiscal 2022 first quarter financial r...
- Announcement Follows First Cases of BA.2 Identified in New York State Where the Majority of COVID-19 Testing Clients Reside - - Linea 1.0 Assay’s Unique Double S-gene Target Design Likely Allows for the Identification of Samples that Contain a Mutation Profile Indicat...
News, Short Squeeze, Breakout and More Instantly...
Applied DNA Sciences Inc. Company Name:
APDN Stock Symbol:
NASDAQ Market:
Applied DNA Sciences Inc. Website:
STONY BROOK, NY / ACCESSWIRE / July 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in PCR-based DNA technologies, today announced that the U.S. Defense Logistics Agency (DLA) exercised the first one-year option period of a three-year base contract with two one-year...
A look at the top 10 most actives in the United States Senti Biosciences Inc. (SNTI) rose 51.3% to $0.4175 on volume of 386,768,896 shares NVIDIA Corporation (NVDA) rose 0.6% to $124.3 on volume of 277,459,318 shares PROSHARES TRUST (SQQQ) fell 1.9% to $8.12 on volume of 139,088,335 share...
- Project Results in over 70% Reduction in Linea RNAP Manufacturing Cost to Yield a Material Improvement in Linea IVT Platform Profitability - - Applied DNA Secures Commercial Linea RNAP Quantity Sufficient to Support Anticipated Near-Term Demand - STONY BROOK, NY AND JUPITER, FL / ACCES...